SIGA (SIGA) Q3 2026 Earnings Call Transcript

Motley Fool Transcribing, The Motley FoolTue, November 10, 2026 at 1:01 AM UTC

0

Image source: The Motley Fool.DATE

Monday, Nov. 9, 2026

CALL PARTICIPANTS -

Chief Executive Officer - Diem Nguyen

Chief Financial Officer - Dan Luckshire

TAKEAWAYS -

Third Quarter Total Revenue -- $1.3 million, decreasing from $2.6 million in the prior-year period due to lower product sales volumes.

Third Quarter Product Sales -- $233,689, reflecting a decrease from $889,748 as the company reported zero deliveries to customers during the three-month period.

Third Quarter R&D Revenue -- $1.1 million, compared to $1.7 million in the third quarter of 2025.

Third Quarter Net Loss -- $2.9 million, representing a narrowing from a net loss of $6.4 million in the prior-year period.

Third Quarter Diluted Loss Per Share -- $0.04, an improvement from a loss of $0.09 per share in the same quarter last year.

Nine-Month Total Revenue -- $48.6 million, down from $90.8 million primarily due to the completion of major delivery cycles.

Nine-Month Product Sales -- $41.6 million, decreasing from $85.8 million as the company finalized several procurement obligations.

Nine-Month R&D Revenue -- $6.9 million, increasing from $4.9 million in the first nine months of the previous year.

Nine-Month Net Income -- $6.1 million, compared to $28.7 million in the prior-year period.

Nine-Month Diluted EPS -- $0.09, down from $0.40 in the first nine months of 2025.

Nine-Month Operating Income -- $2.1 million, decreasing from $33.2 million reflecting different product mixes and delivery volumes.

Cash and Cash Equivalents -- $116.4 million at Sept. 30, 2026, which is a decrease from $155.0 million at the end of 2025 following a special dividend payment.

Debt -- Zero, as the company reported no debt outstanding as of Sept. 30, 2026.

Nine-Month IV TPOXX Deliveries -- $26 million to the U.S. Strategic National Stockpile, fulfilling all final procurement obligations under the BARDA 19C contract.

Nine-Month International Sales -- $13 million, representing deliveries of oral TPOXX to two international customers during the period.

Canadian Contract Value -- Up to approximately $15 million over a five-year period, awarded by the Canadian Department of National Defence in Oct. 2026.

Firm Commitment (Canada) -- $9 million, representing the firm portion of the new Canadian contract to be delivered over the first three years of the agreement.

sNDA Filing Timeline -- 2028, representing a delay for the Post-Exposure Prophylaxis program following an FDA request for additional validation and laboratory work.

Special Cash Dividend -- $0.60 per share, which was declared on March 26, 2026, and paid to shareholders on April 23, 2026.

Phase I Pediatric Study -- Results are expected by Dec. 31, 2026, and will inform future development for expanding therapeutic coverage to infants.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS -

Diem Nguyen noted that the timeline for securing a new U.S. government procurement contract is currently unpredictable, stating, "the process to secure a new U.S. government contract has progressed more slowly than in the past, and the timing of an award remains uncertain."

Nguyen warned that the supplemental NDA for the Post-Exposure Prophylaxis program is now delayed until 2028 because the FDA required additional validation and laboratory work to ensure the accuracy of sample analysis.

SIGA Technologies, Inc. (NASDAQ:SIGA) reported financial results for the third quarter and nine months ended Sept. 30, 2026, marking the completion of its product delivery obligations under the BARDA 19C contract. Management reported that the company is currently focused on securing a new procurement contract with the U.S. government, though the timing of such an award remains uncertain. The company indicated an expansion of its international customer base through a new five-year agreement with the Canadian Department of National Defence and is in advanced negotiations with another international customer. Strategic updates included a timeline revision for the Post-Exposure Prophylaxis supplemental NDA and the upcoming completion of a Phase I pediatric study.

CEO Nguyen stated, "Geopolitical tensions and advances in technology, including AI, are reshaping the threat landscape," requiring proactive government investment in stockpiles.

Management confirmed the retirement of Chief Scientific Officer Dennis Hruby after 30 years with the company, noting he will continue to serve in an advisory capacity.

CFO Luckshire noted that because the Canadian fiscal year runs from April to March, the company could deliver two courses of TPOXX within a single calendar year under the new contract.

Nguyen stated, "historically, smallpox preparedness across Europe has largely been vaccine-centric," while indicating that the company is working to shift the region toward a more comprehensive antiviral stockpiling approach.

Management reported that late-stage negotiations are ongoing for an additional international contract, with further details expected to be provided upon execution.

INDUSTRY GLOSSARY -

BARDA: Biomedical Advanced Research and Development Authority, a U.S. government agency responsible for the procurement and development of medical countermeasures.

CDND: Canadian Department of National Defence.

IV: Intravenous, a method of administering medicine through a vein.

PEP: Post-Exposure Prophylaxis, a treatment started after exposure to a pathogen to prevent infection.

sNDA: Supplemental New Drug Application, an application to the FDA to allow a company to make changes to an already approved drug, such as adding a new indication.

SNS: Strategic National Stockpile, the United States' repository of antibiotics, chemical antidotes, and other medical supplies for use in a public health emergency.

TPOXX: The brand name for tecovirimat, an antiviral medication used to treat smallpox.

Full Conference Call Transcript

Operator: Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations, and are subject to risks and uncertainties that could cause actual results to differ from forward-looking statements. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or changed circumstances after this call.

For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission, including without limitation, the company's annual report on Form 10-K for the year ended December 31st, 2025, and its subsequent reports on Form 10-Q and Form 8-K. With that, I will turn the call over to Diem Nguyen, Chief Executive Officer of SIGA. Diem?

Diem Nguyen: Good afternoon, everyone, and thank you for joining today's call to review our business results. I am joined by Dan Luckshire, our Chief Financial Officer, and we appreciate this opportunity to provide an update on our company. After the update, we will take your questions. Throughout 2026, SIGA has continued to execute on its core mission of working alongside governments to build and sustain long-term preparedness against potential biological threats, namely smallpox. We remain committed to positioning our smallpox therapeutic, TPOXX, for rapid, large-scale deployment should an outbreak occur. As a reminder, in the second quarter, we completed our final product delivery under the BARDA 19C contract, fulfilling all our product obligations under that agreement.

We are proud of this partnership, proud of how we performed, and proud to have played an important role in strengthening the U.S. government's smallpox preparedness. We believe the case for preparedness against biological threats remains strong. Geopolitical tensions and advances in technology, including AI, are reshaping the threat landscape. Mitigating these risks requires proactive, sustained government investment in medical countermeasures stockpiles. In an emergency, ready access to medical countermeasures is essential to protect both civilians and war fighters. At the same time, a compelling case for preparedness does not always translate into predictable procurement.

As we discussed during our last call, the process to secure a new U.S. government contract has progressed more slowly than in the past, and the timing of an award remains uncertain. Even so, we remain confident that TPOXX has an important role in our nation's preparedness plans and that national security for medical countermeasures remain important to the U.S. government. Despite the lack of certainty as to timing and details, based on our discussions with key stakeholders, we continue to believe that a new procurement contract will be awarded. Turning to our international business, I would like to share news of recent contract that advances our efforts to maintain a diverse revenue stream and customer base.

Last month, we signed a contract to supply oral TPOXX to Canada's Department of National Defence, or CDND, over the next five years. This contract is valued up to approximately $15 million. It includes firm commitments about $9 million over the first three years, plus up to $6 million in options exercisable at CDND's discretion. This is CDND's second TPOXX contract. The first, awarded in April of 2020 for the purchase up to approximately $14 million of TPOXX, was completed in 2025. Canada continues to be one of the leaders in smallpox preparedness among our international customers, and we believe this award reflects that commitment. It also highlights another important point.

In a public health emergency, the men and women of the armed forces are often among the first called on to respond, so making sure they have access to smallpox antiviral is a key part of being prepared. Beyond this contract, we are continuing advanced discussions with other international customers, including one which we are in late-stage negotiations. We look forward to providing an update at the appropriate time. Moving to our development activities, I'd like to provide an update on our pediatric formulation and Post-Exposure Prophylaxis, or PEP, programs. We continue to expect results from phase I study of our pediatric formulation by year end, and those results will inform next steps.

If successful, this formulation, together with the oral and IV formulations, would extend TPOXX coverage across the full population, from infants to adults. Children are among the most vulnerable in an outbreak, and an improved pediatric formulation will give governments a more complete solution for their stockpiles. On the PEP program, we continue to work closely with our partners at the Department of War, FDA, and CDC, all of whom remain highly engaged with this program. We recently met with the FDA to review the program, including the immunogenicity sample analysis the CDC plans to conduct.

At that meeting, the FDA has asked us to perform additional validation and related laboratory work to help ensure the accuracy of results from the sample analysis. This work is important and requires time, and as a result, we now expect to file our supplemental NDA in 2028. While this delay is disappointing, it does not change our view on the relevance of this program. In an outbreak, the ability to use TPOXX as a PEP for our military, first responders, and others exposed to smallpox virus can help save lives.

Regarding our financial results, as I said in prior calls, our business is subject to inherent quarter-to-quarter variability, so our results are best viewed over a longer horizon than any single period. Over the first nine months of the year, product revenues totaled approximately $42 million, including sales to the U.S. government and customers in Asia-Pacific region and Europe. That breadth, together with the new CDND contract I talked about earlier, reflects the continued commitment of governments around the world to smallpox preparedness. Before I turn the call over to Dan, I want to recognize Dennis Hruby our Chief Scientific Officer, who is retiring today after three decades with SIGA.

When Dennis joined us in 1996, there was no approved treatment for smallpox. Today, TPOXX is approved in the U.S., Canada, the European Union, the U.K., and Japan. It has been sold to more than 30 countries and is maintained in stockpiles around the world. Dennis's scientific leadership shaped the achievement at every step, from early-stage research through approval. On behalf of everyone at SIGA, I want to thank Dennis for his contributions to our company and to global health security. We're very pleased that he will continue to support us in an advisory role.

In closing, SIGA has always been guided by its mission to ensure governments are prepared to protect their citizens from smallpox, and that mission is unchanged. While procurement processes are not predictable, we stand ready to work with our governments around the world, and we do so with a strong balance sheet, including $116 million in cash and no debt at the end of the quarter. As I said at the start of the call, we believe the case for preparedness remains strong. Smallpox and other high-consequence threats are serious, and emerging technologies have the potential to lower barriers to creating or misusing biologic agents.

With preparation, these threats can be mitigated, and TPOXX has a long history of helping governments meet smallpox threats. With that, I'll turn over to Dan to review our financial results in more detail. Dan?

Dan Luckshire: Thanks, Diem. As noted earlier in the call, the company's product-related revenues are $42 million for the nine months ended September 30th, 2026, with most of the revenues being recorded in the second quarter, reflecting the variable rhythm of SIGA's business model. Year-to-date product revenues include approximately $26 million of IV TPOXX deliveries to the U.S. Strategic National Stockpile and approximately $13 million of international sales to two international customers. For the third quarter, there are no product sales to customers. In addition to product-related revenues for the nine months ended September 30th, 2026, the company also has research and development revenues of approximately $7 million.

Of this total, approximately $1 million of the research and development revenues were earned in the third quarter. Pre-tax operating income for the nine months ended September 30th, 2026, which excludes interest income and taxes, is approximately $2 million. For the quarter, pre-tax operating loss is approximately $7 million. Net income for the nine months ended September 30th, 2026, is approximately $6 million. For the quarter, net loss is approximately $3 million. In turn, fully diluted income per share for the nine months ended September 30th, 2026, is $0.09 per share, while fully diluted loss per share for the quarter is $0.04 per share. The company continues to maintain a strong balance sheet.

At September 30th, 2026, the company had a cash balance of approximately $116 million and no debt. This concludes the financial update. At this point, I will turn the call back to Diem.

Diem Nguyen: Thank you, Dan. With that, we'd like to open the call for questions.

Operator: Thank you. Ladies and gentlemen, we will now begin the question-and-answer session. Should you have a question, please press the star key followed by the number one on your touchtone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press the star key followed by the number two. One moment, please, while we assemble the queue. Your first question comes from Jyoti Prakash of Edison Group. Please go ahead.

Advertisement

Jyoti Prakash: Hi, good evening. Thank you for taking my questions. First of all, congratulations on the recent contract from the CDND. Just want to understand if this is the international opportunity which was highlighted during the Q2 call, and if there's another order still under discussion, because you did mention that you're in conversations. If there is an order under discussion, can we hear about it during the remainder of the year? Going back to the CDND order, can you provide some color on the delivery schedule, particularly if we can expect anything to be delivered within 2027?

Dan Luckshire: Hi, Jyoti. This is Dan. Thanks for the question. I'll answer this one. On the first part of your question, yes, the October contract is the opportunity that we referenced last quarter. In your question, you asked about, well, is there another order? As noted in our prepared remarks, there is another order. We are in advanced stages for another international contract, and on that, we will provide details at the appropriate time. Toward the end of your question, you're talking about sort of cadence of delivery.

With regard to that, the way the contract is set up is the firm orders are structured, so that SIGA would deliver an equal number of oral TPOXX courses in each of the first three fiscal years of the contract. I want to note that given that the Canadian fiscal year goes from April to March, this could result in two deliveries within one calendar year. I wanted to also highlight that deliveries are expected to start in 2027. The contract has the firm orders I just talked about and also has options.

With respect to the options, courses can be ordered and delivered at any point in time during the five-year contract, and that's at the discretion of the Canadian military.

Jyoti Prakash: Thank you, Dan. That was very useful. My second question relates to recent developments and something which has been on people's minds is the results of the U.S. midterm elections. Do you foresee any implications of the results on biodefense funding priorities and possibly the timing of the U.S. RFP?

Diem Nguyen: Hi, Jyoti. This is Diem. Nice to hear your voice, and thanks for joining the call and this question. I would say historically, there has been bipartisan support for biodefense, and quite frankly, biodefense is not a large or controversial budget line item, which means we don't currently expect a change in direction regarding congressional funding for biodefense. As it relates to the new contract process, we currently do not believe that midterm results will have any material impact on the nature or trajectory of this process beyond the typical transition period that follows any election.

Jyoti Prakash: Great. Thank you, Diem. Just going back to international growth, we noted that Bavarian Nordic recently secured a four-year smallpox vaccine contract with the U.K. government. Are you also seeing broader momentum in European preparedness spending and also greater interest in TPOXX? The reason we're asking this is because recently, the Mpox label was removed in Europe. Do you see any sort of implications of this on your recent discussions with the European authorities?

Diem Nguyen: Thanks, Jyoti. So Europe, like many countries and continents, go through multi-year transformational in terms of national security priorities and spending. In this particular environment, each country has its own dynamics and priorities and is moving at its own pace. Overall, yes, we do believe that there's increased focus on biodefense and smallpox preparedness. This has resulted in the spending like the U.K. contract you just mentioned. I would say historically, though, smallpox preparedness across Europe has largely been vaccine-centric. Part of our work supporting a shift towards a more comprehensive approach that pairs vaccines with antivirals, very much similar to the U.S. model, but we do recognize that changing this paradigm takes time.

Specifically for TPOXX, we are part of evolving conversations on stockpiling, both at the country and regional level. Now, Jyoti, for your second question on our European label, in certain cases, the change does require some additional discussion. While this can affect timing, we do not believe it changes the long-term opportunity in Europe for smallpox stockpiling. Notably, just as a gentle reminder, we recently renewed our TPOXX filings both in Europe as well as in U.K. for the treatment of smallpox, and we really look forward to working with our European counterparts in our preparedness efforts.

Jyoti Prakash: That's very helpful. Thanks, Diem. No further questions from my side.

Operator: There are no further questions at this time. I will now turn the call back over to Diem Nguyen. Please continue.

Diem Nguyen: Thank you. Today, I'd like to thank everybody for making time to join us on today's call and for your ongoing interest in SIGA. We look forward to speaking with you again next quarter. Have a good evening.

Operator: Ladies and gentlemen, that concludes today's conference call. Thank you for your participation. You may now disconnect.

Should you buy stock in SIGA Technologies right now?

Before you buy stock in SIGA Technologies, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and SIGA Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $341,966!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,146,819!*

Now, it’s worth noting Stock Advisor’s total average return is 852% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 9, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Original Article on Source

Source: “AOL Money”